A detailed history of Samsara Bio Capital, LLC transactions in Hille Vax, Inc. stock. As of the latest transaction made, Samsara Bio Capital, LLC holds 799,274 shares of HLVX stock, worth $1.49 Million. This represents 0.82% of its overall portfolio holdings.

Number of Shares
799,274
Previous 799,274 -0.0%
Holding current value
$1.49 Million
Previous $11.6 Million 87.83%
% of portfolio
0.82%
Previous 5.94%

Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2023

Nov 14, 2023

BUY
$11.59 - $16.7 $2.32 Million - $3.34 Million
200,000 Added 33.37%
799,274 $10.8 Million
Q2 2023

Aug 14, 2023

SELL
$12.93 - $18.76 $136,902 - $198,630
-10,588 Reduced 1.74%
599,274 $10.3 Million
Q1 2023

May 15, 2023

BUY
$14.73 - $18.18 $8.98 Million - $11.1 Million
609,862 New
609,862 $10.1 Million
Q3 2022

Nov 14, 2022

SELL
$10.5 - $22.01 $1.6 Million - $3.36 Million
-152,515 Reduced 20.0%
610,062 $10.4 Million
Q2 2022

Aug 15, 2022

BUY
$8.7 - $20.18 $6.63 Million - $15.4 Million
762,577 New
762,577 $8.34 Million

Others Institutions Holding HLVX

About HilleVax, Inc.


  • Ticker HLVX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 33,427,200
  • Market Cap $62.5M
  • Description
  • HilleVax, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel vaccines. It is developing HIL-214, a virus-like particle-based vaccine candidate for the prevention of moderate-to-severe acute gastroenteritis caused by norovirus infection. The company is headquartered in Boston, Massachusetts.
More about HLVX
Track This Portfolio

Track Samsara Bio Capital, LLC Portfolio

Follow Samsara Bio Capital, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Samsara Bio Capital, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Samsara Bio Capital, LLC with notifications on news.